A Dravet-syndrome mouse model showed changes in social and memory-related tasks after clonazepam. The result did not establish treatment efficacy for autism in humans.
The researchers examined mice with reduced Scn1a function and targeted changes in inhibitory neurons. The animals showed selected behavioral and cognitive abnormalities, alongside altered inhibitory signaling.
A low-dose clonazepam intervention improved particular social and fear-memory outcomes in the model, supporting a role for the affected inhibitory circuits.
Mouse social-interaction and fear-memory tasks are not diagnoses or complete measures of human social communication. A response in a genetically defined epilepsy model cannot be assigned to all developmental conditions.
The experiment also does not establish that sedation and other unwanted effects are absent at every dose or with long-term treatment. A targeted mechanism in one model can coexist with different responses in other populations.
Keep genotype, species, dose context, and task attached to the finding. The paper may explain a biological hypothesis but cannot show that clonazepam improves a particular child’s cognition, treats autism generally, or that a clinical nonresponse disproves the underlying diagnosis.
Original analysis of the supplied journal article, identified as PMC3448848.